Alyeska Investment Group
CASC

Alyeska Investment Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Alyeska Investment Group’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-52,767
Closed -$867K – 519
2015
Q3 		$867K Buy
52,767
+2,746
+5% +$56.3K 0.01% 399
2015
Q2 		$1.12M Sell
50,021
-74,979
-60% -$1.19M 0.01% 399
2015
Q1 		$1.22M Buy
+125,000
New +$1.23M 0.02% 419

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Alyeska Investment Group's CASC Position: Q4 2015 in Review

Alyeska Investment Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 52,767 shares — an estimated $867K sold.

Alyeska Investment Group first reported a position in CASC in Q1 2015 and held it in 3 quarters. The position peaked at $1.22M in Q1 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Alyeska Investment Group reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 52,767 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $867K.
  • Alyeska Investment Group first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Alyeska Investment Group's Cascadian Therapeutics, Inc. position peaked at $1.22M in Q1 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.